Avelumab plus axitinib in patients with advanced gastrointestinal stromal tumor
The results of the largest trial on the combination of targeted therapy and immunotherapy in pretreated GIST show the promising efficacy of this novel therapeutic approach in a subset of patients.
Authors
- Paweł Teterycz (ORCID: https://orcid.org/0000-0001-7304-714X)
- Anna Klimczak (ORCID: https://orcid.org/0009-0009-8543-8768)
- Maria Concetta Nigro (ORCID: https://orcid.org/0000-0003-3834-6122)
- Maria Abbondanza Pantaleo (ORCID: https://orcid.org/0000-0002-0177-6957)
- Katarzyna Kozak (ORCID: https://orcid.org/0000-0002-3225-422X)
- Paweł Rogala (ORCID: https://orcid.org/0000-0001-7019-9471)
- Jan Poleszczuk (ORCID: https://orcid.org/0000-0001-8758-7200)
- Tomasz Świtaj (ORCID: https://orcid.org/0000-0001-5431-8012)
- Piotr Rutkowski (ORCID: https://orcid.org/0000-0002-8920-5429)
- Margherita Nannini (ORCID: https://orcid.org/0000-0002-2103-1960)
Institutions
- Azienda USL di Bologna (IT)
- National Institute of Oncology (HU)
- Azienda Ospedaliera S.Maria (IT)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Institute of Biocybernetics and Biomedical Engineering (PL)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1016/j.ejca.2025.115565
- Citations
- 3
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.43
Funders
- Pfizer
- Merck KGaA
- European Society for Medical Oncology
- Agencja Badań Medycznych